These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M; Ohl CA Curr Top Microbiol Immunol; 1996; 216():275-97. PubMed ID: 8791745 [No Abstract] [Full Text] [Related]
6. Anti-endotoxin therapeutic options for the treatment of sepsis. Lynn WA J Antimicrob Chemother; 1998 Jan; 41 Suppl A():71-80. PubMed ID: 9511089 [TBL] [Abstract][Full Text] [Related]
8. Targeting the lipopolysaccharides: still a matter of debate? Nahra R; Dellinger RP Curr Opin Anaesthesiol; 2008 Apr; 21(2):98-104. PubMed ID: 18443474 [TBL] [Abstract][Full Text] [Related]
9. Anti-Endotoxin 9-Meric Peptide with Therapeutic Potential for the Treatment of Endotoxemia. Krishnan M; Choi J; Choi S; Kim Y J Microbiol Biotechnol; 2021 Jan; 31(1):25-32. PubMed ID: 33263333 [TBL] [Abstract][Full Text] [Related]
10. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Barriere SL; Guglielmo BJ Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812 [TBL] [Abstract][Full Text] [Related]
12. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. Maury E; Blanchard HS; Chauvin P; Guglielminotti J; Alzieu M; Guidet B; Offenstadt G J Crit Care; 2003 Jun; 18(2):115-20. PubMed ID: 12800122 [TBL] [Abstract][Full Text] [Related]
13. Targeting endotoxin in the treatment of sepsis. Rachoin JS; Schorr CA; Dellinger RP Subcell Biochem; 2010; 53():323-38. PubMed ID: 20593274 [TBL] [Abstract][Full Text] [Related]
14. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464 [TBL] [Abstract][Full Text] [Related]
15. Current prospects for the treatment of clinical sepsis. Suffredini AF Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188 [TBL] [Abstract][Full Text] [Related]
16. Traditional and high potency probiotic preparations for oral bacteriotherapy. Famularo G; De Simone C; Matteuzzi D; Pirovano F BioDrugs; 1999 Dec; 12(6):455-70. PubMed ID: 18031194 [TBL] [Abstract][Full Text] [Related]
17. Endotoxin as a therapeutic target in septic shock. Corriveau CC; Danner RL Infect Agents Dis; 1993 Feb; 2(1):35-43. PubMed ID: 8162352 [TBL] [Abstract][Full Text] [Related]
19. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Opal SM Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016 [TBL] [Abstract][Full Text] [Related]
20. Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria. Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Orlando F; Silvestri C; Bozzi A; Di Giulio A; Luzi C; Mangoni ML; Barra D; Saba V; Scalise G; Rinaldi AC Antimicrob Agents Chemother; 2006 Jul; 50(7):2478-86. PubMed ID: 16801429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]